

Lincoral-S 222 mg/g + 444.7 mg/g powder for use in drinking water

Authorised

- Spectinomycin sulfate tetrahydrate
- Lincomycin hydrochloride monohydrate

Product identification

Medicine name:

Lincoral-S 222 mg/g + 444.7 mg/g powder for use in drinking water

Active substance:

Spectinomycin sulfate tetrahydrate

Lincomycin hydrochloride monohydrate

Target species:

Chicken

Pig

Route of administration:

In drinking water use

Product details

Active substance and strength:

Spectinomycin sulfate tetrahydrate

672.40 milligram(s) / 1.00 gram(s)

Lincomycin hydrochloride monohydrate

251.70 milligram(s) / 1.00 gram(s)

Pharmaceutical form:

Powder for use in drinking water

Withdrawal period by route of administration:

In drinking water use:

-

Chicken

- Eggs. no withdrawal period

Not for use in birds producing or intended to produce eggs for human consumption.

- Meat and offal. 5 day

Animals must not be slaughtered for human consumption during treatment.

-

Pig

- Meat and offal. 0 day

Animals must not be slaughtered for human consumption during treatment.

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01FF52

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Ireland

Package description:

150 g thermos-sealed sachets made of polyethylene/aluminum/polyester

1.5 kg thermos-sealed bags made of polyethylene/aluminum/polyester

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

HuVepharma

Marketing authorisation date:

8/09/2023

Manufacturing sites for batch release:

Huvepharma S.A.

Responsible authority:

Health Products Regulatory Authority

Authorisation number:

VPA10782/041/001

Date of authorisation status change:

8/09/2023

Reference member state:

Ireland

Procedure number:

IE/V/0668/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Greece
Hungary Iceland Italy Latvia Lithuania Luxembourg Malta Netherlands
Poland Portugal Romania Slovakia Slovenia Spain

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet